Drug Profile

Research programme: chimeric antigen receptor T-cell therapies - AbbVie/California Institute for Biomedical Research

Latest Information Update: 09 Feb 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Research Autoimmune disorders; Solid tumours
No development reported Fibrosis; Immunological disorders; Neurological disorders

06 Feb 2024 CAR-T cell therapies is still in preclinical development for Solid tumours in USA
06 Feb 2024 AbbVie expands option and license agreement with California Institute for Biomedical Research to develop CAR-T cell therapies for Solid tumours and Autoimmune disorders
06 Feb 2024 Early research in Autoimmune disorders in USA (Parenteral), prior to February 2024

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com